Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Inventors

Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Changgeng • Bao, Rudi

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11135205-B2

Patent

Publication Date

2021-10-05

Expiration Date


Abstract

The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Core Innovation

The disclosure describes phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) multi-target therapeutic compounds centered on Compound 1 and a zinc-binding HDAC inhibitor and PI3K inhibitor framework according to Formula I. The compounds are presented with general chemical framework and aspects including salts and pharmaceutically acceptable compositions.

The patent describes synthesizing key intermediates, including Intermediate 108-1 and Intermediate 108-2, by coupling thienopyrimidine-based chlorides with substituted pyridyl boronic acid derivatives. It then describes forming the PI3K/HDAC inhibitor series, including Compound 1, through conversion of a carboxamide precursor to an N-hydroxy carboxamide using hydroxylamine.

The disclosed compounds are described as producing PI3K/HDAC inhibition and associated biological effects, including antiproliferative effects and antitumor efficacy in xenograft models following oral or intravenous dosing. The document also describes pharmacodynamics effects including tumor uptake and network disruption through PI3K-AKT-mTOR and RAF-MEK-ERK pathway effects, along with cell-cycle arrest and apoptosis associated with p53/p21, and reversible lymphopenia.

Claims Coverage

The provided portion includes one independent claim. This claim covers a combination treatment of Compound 1, or a pharmaceutically acceptable salt, with lenalidomide for treating a hematological cancer in a subject, using therapeutically effective amounts. Dependent claims further refine the hematological cancer subtype and administration timing, including simultaneous or sequential administration.

Treating hematological cancer with Compound 1 and lenalidomide

A method of treating a hematological cancer in a subject in need thereof, comprising administering Compound 1 or a pharmaceutically acceptable salt thereof and lenalidomide in amounts which together are therapeutically effective.

Simultaneous administration of Compound 1 and lenalidomide

The method administers Compound 1 or a pharmaceutically acceptable salt thereof and lenalidomide simultaneously in the therapeutically effective amounts together.

Sequential administration of Compound 1 and lenalidomide

The method administers Compound 1 or a pharmaceutically acceptable salt thereof and lenalidomide sequentially in the therapeutically effective amounts together.

Lymphocytic leukemia indication

The method of treating a hematological cancer is performed for lymphocytic leukemia.

Acute lymphoblastic leukemia indication

The method is performed for acute lymphoblastic leukemia.

Myelodysplastic syndrome indication

The method is used for treating a hematological cancer specifically identified as myelodysplastic syndrome.

Across the claims provided, the core coverage is a therapeutically effective combination of Compound 1, or a pharmaceutically acceptable salt, with lenalidomide for treating hematological cancers, with further claim coverage for specific leukemia subtypes, including lymphocytic and acute lymphoblastic, and for myelodysplastic syndrome, and with refinement of administration timing into simultaneous or sequential administration.

Stated Advantages

Potent inhibition in PI3K isoforms and potent HDAC inhibition with isoform selectivity is described in the disclosure.

Potent PI3K/HDAC inhibition.

Cell antiproliferative activity across many cancer cell lines is described.

Antiproliferative effects.

In vivo antitumor activity and PK/PD are described.

Antitumor efficacy in xenograft tumor models after oral or intravenous dosing.

Combination efficacy with lenalidomide is described.

Tumor network disruption via PI3K-AKT-mTOR and RAF-MEK-ERK pathway effects.

Cell-cycle arrest and apoptosis associated with p53/p21.

Reversible lymphopenia.

Oral bioavailability and suitability for oral formulation.

Genotoxicity assessment via an Ames test (safety-related context).

Documented Applications

Treating a hematological cancer in a subject in need thereof using Compound 1 or a pharmaceutically acceptable salt together with lenalidomide.

Treating leukemia, including lymphocytic leukemia.

Treating acute lymphoblastic leukemia.

Treating myelodysplastic syndrome.

Therapeutic treatment of cancers, including leukemia/lymphoma types and myelodysplastic syndrome.

Treatment of disorders described as PI3K- and HDAC-linked.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.